ZCOR - Zyla Life Sciences

Other OTC - Other OTC Delayed Price. Currency in USD
2.0999
-0.0001 (-0.00%)
At close: 12:14PM EDT
Stock chart is not supported by your current browser
Previous Close2.1000
Open2.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.0999 - 2.1000
52 Week Range2.0900 - 3.0500
Volume200
Avg. Volume11,560
Market Cap19.657M
Beta (3Y Monthly)N/A
PE Ratio (TTM)7.39
EPS (TTM)0.2840
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • CNW Group26 days ago

    Growth Public Company Investor Presentations Now Available for On-Demand Viewing

    Growth Public Company Investor Presentations Now Available for On-Demand Viewing

  • Zyla Life Sciences Appoints Dr. Gary M. Phillips to Board of Directors
    PR Newswirelast month

    Zyla Life Sciences Appoints Dr. Gary M. Phillips to Board of Directors

    WAYNE, Pa., June 19, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a growing commercial-stage life sciences company, announced the appointment of Gary M. Phillips, M.D. to its board of directors. "Gary brings to Zyla a wealth of experience from working in the pharmaceutical industry in a range of commercial, business development, strategy and clinical development leadership positions," said Timothy P. Walbert, Zyla chairman of the board and chairman, president and chief executive officer (CEO) of Horizon Therapeutics.

  • CNW Grouplast month

    Live Investor Conference & Webinar June 20th

    Live Investor Conference & Webinar June 20th

  • Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer
    PR Newswirelast month

    Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer

    WAYNE, Pa., June 12, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a growing commercial-stage life sciences company, announced the appointment of H. Jeffrey Wilkins, M.D. as senior vice president and chief medical officer (CMO) effective immediately. "With extensive clinical development, medical affairs and product evaluation experience, Dr. Wilkins brings invaluable capabilities as we continue to grow Zyla Life Sciences," said Bob Radie, president and chief executive officer.

  • Egalet Reports First Quarter 2019 Financial Results and Plan to Change Company Name to Zyla Life Sciences
    PR Newswire2 months ago

    Egalet Reports First Quarter 2019 Financial Results and Plan to Change Company Name to Zyla Life Sciences

    -- Acquisition of five new products completed increasing net product sales to $17.6 million - an increase of more than 100% from the fourth quarter 2018 and 180% from the first quarter 2018 -- -- SG&A ...

  • Egalet to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on May 16, 2019
    PR Newswire2 months ago

    Egalet to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on May 16, 2019

    WAYNE, Penn., May 14, 2019 /PRNewswire/ -- Egalet Corporation (ZCOR) ("Egalet"), a commercial-stage life sciences company focused on marketing treatments for different types of pain and inflammation, today announced that its first quarter 2019 financial results will be released on Thursday, May 16, 2019. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a commercial-stage life sciences company, is focused on marketing treatments for different types of pain and inflammation.